Hui Cheng

Summary

Affiliation: Thomas Jefferson University
Country: USA

Publications

  1. ncbi Targeting GSK-3 family members in the heart: a very sharp double-edged sword
    Hui Cheng
    Center for Translational Medicine and Cardiology Division, Thomas Jefferson University Hospital, Philadelphia, PA, USA
    J Mol Cell Cardiol 51:607-13. 2011
  2. ncbi Why do kinase inhibitors cause cardiotoxicity and what can be done about it?
    Hui Cheng
    Center for Translational Medicine and Cardiology Division, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Prog Cardiovasc Dis 53:114-20. 2010
  3. ncbi A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity
    Hui Cheng
    Center for Translational Medicine, The Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Circ Res 109:1401-9. 2011
  4. ncbi Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics
    Hui Cheng
    Center for Translational Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Circ Res 106:21-34. 2010

Detail Information

Publications4

  1. ncbi Targeting GSK-3 family members in the heart: a very sharp double-edged sword
    Hui Cheng
    Center for Translational Medicine and Cardiology Division, Thomas Jefferson University Hospital, Philadelphia, PA, USA
    J Mol Cell Cardiol 51:607-13. 2011
    ..This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure."..
  2. ncbi Why do kinase inhibitors cause cardiotoxicity and what can be done about it?
    Hui Cheng
    Center for Translational Medicine and Cardiology Division, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Prog Cardiovasc Dis 53:114-20. 2010
    ..Herein we will explore the mechanisms underlying the cardiotoxicity of small-molecule KIs, hoping to explain how and why this happens, and will further examine strategies to deal with the problem...
  3. ncbi A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity
    Hui Cheng
    Center for Translational Medicine, The Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Circ Res 109:1401-9. 2011
    ..Sorafenib is a KI of concern because it inhibits growth factor receptors and Raf-1/B-Raf, kinases that are upstream of extracellular signal-regulated kinases (ERKs) and signal cardiomyocyte survival in the setting of stress...
  4. ncbi Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics
    Hui Cheng
    Center for Translational Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Circ Res 106:21-34. 2010
    ....